British scientists will apply this year to start patient trials of an embryonic stem-cell therapy for the commonest cause of blindness.
If approved, the study will be the second of its kind, after US regulators yesterday cleared the first human trial of the powerful master cells. The US decision to approve the trial of a paralysis treatment by the Geron Corporation will open the way for a team at University College London to test a similar therapy for age-related macular degeneration (AMD) on patients.
http://www.timesonline.co.uk/tol/news/uk/science/article5576335.ece